SBRA

Sabra Health Care REIT Inc

Add to Watchlist

Advanced Chart

18.640

-0.08(-0.427%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

18.850

Open

18.760

VWAP

18.67

Vol

2.19M

Mkt Cap

4.47B

Low

18.550

Amount

40.85M

EV/EBITDA(TTM)

25.24

Total Shares

231.50M

6.85B

EV/OCF(TTM)

20.23

P/S(TTM)

6.09

Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. Its primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Its investment portfolio primarily comprises skilled nursing/transitional care facilities, senior housing communities (Senior Housing - Leased), behavioral health facilities, and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed); investments in joint ventures; loans receivable, and preferred equity investments. Its real estate properties held for investment included 37,047 beds/units, spread across the United States and Canada.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

190.27M

+6.89%

192.29M

+5.45%

190.04M

+3.54%

Estimates Revision

The market is revising Downward the revenue expectations for Sabra Health Care REIT, Inc. (SBRA) for FY2025, with the revenue forecasts being adjusted by -1.37% over the past three months. During the same period, the stock price has changed by 4.13%.

Revenue Estimates for FY2025

Revise Downward

-1.37%

In Past 3 Month

Stock Price

Go Up

+4.13%

In Past 3 Month

5 Analyst Rating

4.08% Upside

Wall Street analysts forecast SBRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBRA is 19.40 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

4.08% Upside

Current: 18.640

Low

18.00

Averages

19.40

High

20.00

4.08% Upside

Current: 18.640

Low

18.00

Averages

19.40

High

20.00

Citizens JMP

Outperform

maintain

$20 -> $22

2025-08-06

Reason

Citizens JMP

Price Target

$20 -> $22

2025-08-06

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Sabra Health Care to $22 from $20 and keeps an Outperform rating on the shares following the Q2 results. The portfolio is performing exceptionally well, with coverage ratios expanding across every category and same-store Senior Housing Operating Portfolio NOI growing by 17%, the analyst tells investors in a research note.

Scotiabank

Sector Perform

maintain

$19 -> $20

2025-06-23

Reason

Scotiabank

Price Target

$19 -> $20

2025-06-23

maintain

Sector Perform

Reason

Scotiabank raised the firm's price target on Sabra Health Care to $20 from $19 and keeps a Sector Perform rating on the shares. Scotiabank notes recent results point to expected move-in pace remaining strong in Spring 2025 and the firm continues to see landlord pricing power since analyses show assisted living screens as more affordable than home care in the majority of REIT markets, the analyst tells investors.

Scotiabank

Nicholas Yulico

Sector Perform

maintain

$18 -> $19

2025-05-12

Reason

Scotiabank

Nicholas Yulico

Price Target

$18 -> $19

2025-05-12

maintain

Sector Perform

Reason

Scotiabank analyst Nicholas Yulico raised the firm's price target on Sabra Health Care to $19 from $18 and keeps a Sector Perform rating on the shares. The firm is adjusting its estimates on U.S. Real Estate & REITs in its coverage following Q1 results, the analyst tells investors. Quarterly results contained some negative surprises, but generally played out as expected, with most companies maintaining FY25 guidance, the firm notes. Real estate fundamentals tend to lag, so many are looking to see the potential impact of the slowing economy on H2 2025 results, the firm adds.

Truist Securities

Michael Lewis

Hold

Maintains

$17 → $18

2025-03-18

Reason

Truist Securities

Michael Lewis

Price Target

$17 → $18

2025-03-18

Maintains

Hold

Reason

Truist raised the firm's price target on Sabra Health Care to $18 from $17 and keeps a Hold rating on the shares. The risk of recession has increased and the 10-year Treasury rate has fallen since the firm's downgrade of the stock in January, the analyst tells investors in a research note. Notwithstanding risks to Medicaid funding, select healthcare REITs might generally be relatively defensive within the sector if macroeconomic trends continue to worsen, Truist adds.

Citizens Capital Markets

Matthew Carletti

Buy

Reiterates

$20

2025-02-21

Reason

Citizens Capital Markets

Matthew Carletti

Price Target

$20

2025-02-21

Reiterates

Buy

Reason

Truist Securities

Michael Lewis

Strong Buy

Hold

Downgrades

$18 → $17

2025-01-17

Reason

Truist Securities

Michael Lewis

Price Target

$18 → $17

2025-01-17

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sabra Health Care REIT Inc (SBRA.O) is 24.75, compared to its 5-year average forward P/E of 27.15. For a more detailed relative valuation and DCF analysis to assess Sabra Health Care REIT Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

27.15

Current PE

24.75

Overvalued PE

57.24

Undervalued PE

-2.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Overvalued

5Y Average EV/EBITDA

13.18

Current EV/EBITDA

14.48

Overvalued EV/EBITDA

14.18

Undervalued EV/EBITDA

12.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.22

Current PS

5.87

Overvalued PS

5.92

Undervalued PS

4.51